Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial

被引:6
|
作者
van Nes, J. G. H. [1 ]
Seynaeve, C. [2 ]
Maartense, E. [3 ]
Roumen, R. M. H. [4 ]
de Jong, R. S. [5 ]
Beex, L. V. A. M. [6 ]
Kranenbarg, W. M. Meershoek-Klein [7 ]
Putter, H. [8 ]
Nortier, J. W. R. [9 ]
van de Velde, C. J. H. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands
[2] Daniel Denhoed Canc Ctr, Erasmus Med Ctr, Dept Med Oncol, Rotterdam, Netherlands
[3] Reinier Graaf Gasthuis, Dept Internal Med, Delft, Netherlands
[4] Maxima Med Ctr, Dept Surg, Veldhoven, Netherlands
[5] Martini Hosp, Dept Internal Med, Groningen, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands
[7] Leiden Univ, Med Ctr, Datactr Surg, NL-2300 RC Leiden, Netherlands
[8] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands
[9] Leiden Univ, Med Ctr, Dept Med Oncol, NL-2300 RC Leiden, Netherlands
关键词
breast cancer; endocrine therapy; guideline; patterns of care; AROMATASE INHIBITORS; THERAPY; WOMEN; SURVIVAL; RECOMMENDATIONS; NETHERLANDS; MASTECTOMY; MANAGEMENT; LETROZOLE; SURGERY;
D O I
10.1093/annonc/mdp419
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Methods: Clinicopathological characteristics, carried out local treatment strategies and adjuvant chemotherapy data were collected. Results: From 2001 to January 2006, 2754 Dutch patients were randomised to the study. Mean age of patients was 65 years (standard deviation 9). Tumours were < 2 cm in 46% (within CCCRs 39%-50%), node-negative disease varied from 25% to 45%, and PgR status was determined in 75%-100% of patients. Mastectomy was carried out in 55% (45%-70%), sentinel lymph node procedure in 68% (42%-79%) and axillary lymph node dissections in 77% (67%-83%) of patients, all different between CCCRs (P < 0.0001). Adjuvant chemotherapy was given in 15%-70% of eligible patients (P < 0.001). Discussion: In spite of national guidelines, breast cancer treatment on specific issues widely varied between the various Dutch regions. These data provide valuable information for breast cancer organisations indicating (lack of) guideline adherence and areas for breast cancer care improvement.
引用
收藏
页码:974 / 982
页数:9
相关论文
共 50 条
  • [41] Specific Adverse Events Predict Survival Benefit in Early Breast Cancer Patients Treated with Exemestane in the Dutch/Belgian TEAM Trial
    Fontein, D.
    Houtsma, D.
    Hille, E. T. M.
    Kranenbarg, W. M. Meershoek-Klein
    Putter, H.
    Seynaeve, C.
    Dirix, L. Y.
    Paridaens, R.
    van de Velde, C. J. H.
    Nortier, J. W. R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S101 - S101
  • [42] Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)-a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen
    Bertelli, G.
    Hall, E.
    Ireland, E.
    Snowdon, C. F.
    Jassem, J.
    Drosik, K.
    Karnicka-Mlodkowska, H.
    Coombes, R. C.
    Bliss, J. M.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 498 - 505
  • [43] Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis (vol 7, pg 991, 2006)
    Jonat, W.
    Gnant, M.
    Boccardo, F.
    LANCET ONCOLOGY, 2007, 8 (01): : 6 - 6
  • [44] Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
    Binghe Xu
    Huiping Li
    Zefei Jiang
    Lin Gu
    Jinhai Tang
    Hui Xie
    Yueyin Pan
    Yunjiang Liu
    Shude Cui
    Xiaojia Wang
    Li Cai
    Yiqiong Zhang
    Huadong Zhao
    Zhimin Shao
    Chinese Journal of Cancer Research, 2022, 34 (06) : 592 - 601
  • [45] Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
    Xu, Binghe
    Li, Huiping
    Jiang, Zefei
    Gu, Lin
    Tang, Jinhai
    Xie, Hui
    Pan, Yueyin
    Liu, Yunjiang
    Cui, Shude
    Wang, Xiaojia
    Cai, Li
    Zhang, Yiqiong
    Zhao, Huadong
    Shao, Zhimin
    CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (06) : 592 - +
  • [46] Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG trial 8 and the ARNO 95 trial
    Jakesz, R
    Kaufmann, M
    Gnant, M
    Jonat, W
    Mittlboeck, M
    Greil, R
    Tausch, C
    Hilfrich, J
    Kwasny, W
    Samonigg, H
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S7 - S7
  • [47] Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
    Machin, D
    Andersen, KW
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (09): : 659 - 659
  • [48] Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
    Rutqvist, LE
    Hatschek, T
    Ryden, S
    Bergh, J
    Bengtsson, NO
    Carstenssen, J
    Nordenskjold, B
    Wallgren, A
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21) : 1543 - 1549
  • [49] Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
    C. Louwrens Braal
    Agnes Jager
    Esther Oomen-de Hoop
    Justin D. Westenberg
    Koen M. W. T. Lommen
    Peter de Bruijn
    Mijntje B. Vastbinder
    Quirine C. van Rossum-Schornagel
    Martine F. Thijs-Visser
    Robbert J. van Alphen
    Liesbeth E. M. Struik
    Hanneke J. M. Zuetenhorst
    Ron H. J. Mathijssen
    Stijn L. W. Koolen
    Clinical Pharmacokinetics, 2022, 61 : 527 - 537
  • [50] Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
    Braal, C. Louwrens
    Jager, Agnes
    Oomen-de Hoop, Esther
    Westenberg, Justin D.
    Lommen, Koen M. W. T.
    de Bruijn, Peter
    Vastbinder, Mijntje B.
    Van Rossum-Schornagel, Quirine C.
    Thijs-Visser, Martine F.
    van Alphen, Robbert J.
    Struik, Liesbeth E. M.
    Zuetenhorst, Hanneke J. M.
    Mathijssen, Ron H. J.
    Koolen, Stijn L. W.
    CLINICAL PHARMACOKINETICS, 2022, 61 (04) : 527 - 537